COMP <GO>
KRMD vs JNJ // REVENUE GROWTH (YOY)
KORU Medical Systems Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: KRMD 2
— JNJ 8
▲ REVENUE GROWTH (YOY) LEADER: KRMD
LAST: $3.23 (+0.31%) • MKT CAP: $149.1M
revenue-growth
22.20%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRMD VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KRMD | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.30% | 67.90% | -5.60 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.70% | 25.50% | -54.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.31% | 2.97% | -2.66 | JNJ | /fcf-yield <GO> |
| Operating Margin | -7.20% | 34.70% | -41.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -6.40% | 28.50% | -34.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 22.20% | 6.00% | +16.20 | KRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.05 | 5.59 | +2.46 | KRMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.8 | 62.1 | -6.30 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $149.1M | $662.49B | -$662.34B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KRMD REV | JNJ REV | KRMD GROSS % | JNJ GROSS % | KRMD FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $41.1M | $94.19B | 62.3% | 67.9% | $462.4K | $19.70B |
| FY 2024 | $33.6M | $88.82B | 63.4% | 69.1% | -$319.7K | $19.84B |
| FY 2023 | $28.5M | $85.16B | — | — | -$4.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRMD // BETA —
JNJ // BETA 1.08